Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25352826 | 1.00 | CA1 (0.44) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL30299067 | 0.97 | CA1 (0.44) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL20556384 | 0.93 | CA1 (0.45) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL20556383 | 0.93 | CA1 (0.45) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL25352953 | 0.91 | MMP2 (0.50) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL25352949 | 0.91 | MMP2 (0.50) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL25354041 | 0.89 | MMP2 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL12287583 | 0.89 | MMP2 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL25354045 | 0.89 | MMP2 (0.46) | CA1CA2MMP2MMP9MMP1 | |
| SCHEMBL30517734 | 0.87 | MMP9 (0.41) | CA1CA2MMP2MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118510788-A | Liposoamines | 摩登纳特斯有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | CA1 4350/4885CA2 4557/4885MMP2 3646/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | CA1 1889/4885CA2 3992/4885MMP2 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.